This position paper highlights the potential of in silico medicine, using computational modelling and simulation to aid drug discovery, development, and delivery. It calls for adaptation of in silico technology to be a standard practice to complement in vivo and in vitro approaches in healthcare through a collaborative ecosystem of stakeholders.
"The potential of in silico approaches to streamline drug development" is a position paper written by a range of authors across academia and industry, representing both the VPHi and the Avicenna Alliance.
In silico methods have been suggested to reduce time, cost, and environmental footprint of the regulatory approval process. However, the impact of in silico methods in regulatory decision-making and post-market surveillance remains limited. Hence, there is a strong need to develop industrial infrastructure and regulatory framework to actively incorporate in silico technology to foster medical innovation and overcome the hurdles in drug development process.
Read the full document here
